nach oben

Drug Safety

Erschienen in:

01.01.2006 | Review Article

Botulinum Toxin Treatment of Adult Spasticity

A Benefit-Risk Assessment

verfasst von: Dr Geoffrey Sheean

Erschienen in: Drug Safety | Ausgabe 1/2006

Einloggen, um Zugang zu erhalten

Abstract

Injections of botulinum toxin have revolutionised the treatment of focal spasticity. Before their advent, the medical treatment for focal spasticity involved oral antispasticity drugs, which had decidedly non-focal adverse effects, and phenol injections. Phenol injections could be difficult to perform, could cause sensory complications and had effects that were of uncertain duration and magnitude. Furthermore, few neurologists knew how to perform them as they were mostly the province of rehabilitation specialists. Botulinum toxin can produce focal, controllable muscle weakness of predictable duration, without sensory adverse effects.

Randomised clinical trials (RCTs) involving patients with spasticity resulting f r om a variety of diseases (mainly stroke and multiple sclerosis) have clearly shown that botulinum toxin type A (Dysport® and Botox®) can temporarily (for approximately 3 months) reduce spastic hypertonia in the elbow, wrist and finger flexors of the upper limbs, and the hip adductors and ankle plantarflexors in the lower limbs. The clinical benefits from this reduction of neurological impairment are best shown in the upper limb, with less disability of passive function and reduced caregiver burden. In the lower limbs, there is improved perineal hygiene from hip adductor injections. The benefits of reducing ankle plantarflexor tone are less well established. Pain is also reduced, possibly by mechanisms other than muscle weakness. Improved active function has not yet been clearly demonstrated in RCTs, only in open-label trials. The safety of botulinum toxin-A is impressive, with minimal (mainly local) adverse effects.

There are little data on the use of botulinum toxin type B (Myobloc® or Neurobloc®) in spasticity and the only RCT that has examined this did not show tone reduction; dry mouth appeared to be a very common adverse effect. There are also very little data to allow a benefit-risk comparison of phenol and botulinum toxin injections; each have their clinical and technical advantages and disadvantages, and phenol is much less costly than botulinum toxin.

The use of trade names is for product identification purposes only and does not imply endorsement.

Naumann M, Toyka KV, Moore P. History and current applications of botulinum toxin: from poison to remedy. In: Naumann P, Moore P, editors. Handbook of botulinum toxin treatment. 2nd ed. Cambridge (MA), Blackwell Science, 2003: 3–8

Brin MF, Aoki KR. Botulinum toxin type A: pharmacology. In: Mayer NH, Simpson DM, editors. Spasticity: etiology, evaluation, management and the role of botulinum toxin. New York(NY): WeMove Organization, 2002: 110–24

Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003 Jul-Aug; 43Suppl 1: S9–15PubMedCrossRef

Berweck S, Heinen F. Use of botulinum toxin in pediatric spasticity (cerebral palsy). Mov Disord 2004 Mar; 19Suppl. 8: S162–7PubMedCrossRef

Wong V. Evidence-based approach of the use of Botulinum toxin type A (BTX) in cerebral palsy. Pediatr Rehabil 2003 Apr-Jun; 6(2): 85–96PubMed

Sheean G. Use of botulinum toxin for spasticity. Expert Rev Neurother 2003; 3(6): 773–85PubMedCrossRef

Sheean G. The treatment of musculoskeletal pain and spasm with botulinum toxin. Curr Pain Headache Rep 2002; 6: 460–9PubMedCrossRef

Sheean G. Neurophysiology of Spasticity. In Barnes MP, Johnson G, editors. Clinical management of spasticity and the upper motor neurone syndrome. Cambridge: Cambridge University Press, 2001: 12–78

Lance JW. Symposium synopsis. In: Feldman RG, Young RR, Koella WP, editors. Spasticity: disordered motor control. Chicago: Year Book Medical Publishers, 1980: 485–94

10.

Mayer NH, Simpson DM. Preface. In: Mayer NH, Simpson DM, editors. Spasticity: etiology, evaluation, management and the role of botulinum toxin. New York(NY): We Move Organization, 2002

11.

Bhakta BB, Cozens JA, Chamberlain MA, et al. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 2000; 69: 217–21PubMedCrossRef

12.

Landau WM. Spasticity: the fable of a neurological demon and the emperor’s new therapy. Arch Neurol 1974; 31: 217–9PubMedCrossRef

13.

Landau WM. Tizanidine and spasticity: neuromythology XIV. Neurology 1995; 45: 2295–6PubMedCrossRef

14.

Landau WM. Botulinum toxin for spasticity after stroke. N Engl J Med 2003 Jan 16; 348(3): 258–9PubMedCrossRef

15.

Dietz V. Spastic movement disorder: what is the impact of research on clinical practice? J Neurol Neurosurg Psychiatry 2003 Jun; 74(6): 820–1PubMedCrossRef

16.

Snow BJ, Tsui JK, Bhatt MH, et al. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol 1990; 28:512–5PubMedCrossRef

17.

Simpson DM, Alexander DN, O’Brien CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1996; 46: 1306–10PubMedCrossRef

18.

Burbaud P, Wiart L, Dubos JL, et al. A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry 1996; 61: 265–9PubMedCrossRef

19.

Bakheit AM, Thilmann AF, Ward AB, et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000; 31: 2402–6PubMedCrossRef

20.

Richardson D, Sheean G, Werring D, et al. Evaluating the role of botulinum toxin in the management of focal hypertonia in adults. J Neurol Neurosurg Psychiatry 2000; 69: 499–506PubMedCrossRef

21.

Hyman N, Barnes M, Bhakta B, et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 2000; 8: 707–12CrossRef

22.

Smith SJ, Ellis E, White S, et al. A double-blind placebocontrolled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil 2000; 14: 5–13PubMedCrossRef

23.

Bakheit AM, Pittock S, Moore AP, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol 2001; 8(6): 559–65PubMedCrossRef

24.

Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002, 400

25.

Pittock SJ, Moore AP, Hardiman O, et al. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport®) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis 2003; 15(4): 289–300PubMedCrossRef

26.

Brashear A, McAfee AL, Kuhn ER, et al. Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. Arch Phys Med Rehabil 2004 May; 85(5): 705–9PubMedCrossRef

27.

Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964 Apr; 192: 540–2PubMed

28.

Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987 Feb; 67(2): 206–7PubMed

29.

Sheean GL. Botulinum treatment of spasticity: why is it so difficult to show a functional benefit? Curr Opin Neurol 2001 Dec; 14(6): 771–6PubMedCrossRef

30.

Bakheit AM. Optimising the methods of evaluation of the effectiveness of botulinum toxin treatment of post-stroke muscle spasticity. J Neurol Neurosurg Psychiatry 2004 May; 75(5): 665–6PubMedCrossRef

31.

Satila H, Iisalo T, Pietikainen T, et al. Botulinum toxin treatment of spastic equinus in cerebral palsy: a randomized trial comparing two injection sites. Am J Phys Med Rehabil 2005; 84: 355–65PubMedCrossRef

32.

Steenbeek D, Meester-Delver A, Becher JG, et al. The effect of botulinum toxin type A treatment of the lower extremity on the level of functional abilities in children with cerebral palsy: evaluation with goal attainment scaling. Clin Rehabil 2005; 19: 274–82PubMedCrossRef

33.

Fehlings D, Rang M, Glazier J, et al. An evaluation of botulinum- A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. J Pediatr 2000; 137: 331–7PubMedCrossRef

34.

Koman LA, MooneyIII JF, Smith BP, et al. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group. J Pediatr Orthop 2000; 20: 108–15PubMed

35.

Brashear A, McAfee AL, Kuhn ER, et al. Treatment with botulinum toxin type B for upper-limb spasticity. Arch Phys Med Rehabil 2003 Jan; 84 (1): 103–7CrossRef

36.

Francis HP, Wade DT, Turner-Stokes L, et al. Does reducing spasticity translate into functional benefit? An exploratory meta-analysis. J Neurol Neurosurg Psychiatry 2004 Nov; 75 (11): 1547–51CrossRef

37.

Bhakta BB, Cozens JA, Bamford JM, et al. Use of botulinum toxin in stroke patients with severe upper limb spasticity. J Neurol Neurosurg Psychiatry 1996 Jul; 61(1): 30–5PubMedCrossRef

38.

Dengler R, Neyer U, Wohlfarth K, et al. Local botulinum toxin in the treatment of spastic drop foot. J Neurol 1992 Aug; 239(7): 375–8PubMed

39.

Dunne JW, Heye N, Dunne SL. Treatment of chronic limb spasticity with botulinum toxin A. J Neurol Neurosurg Psychiatry 1995 Feb; 58(2): 232–5PubMedCrossRef

40.

Fock J, Galea MP, Stillman BC, et al. Functional outcome following Botulinum toxin A injection to reduce spastic equinus in adults with traumatic brain injury. Brain Inj 2004 Jan; 18(1): 57–63PubMedCrossRef

41.

Hesse S, Lucke D, Malezic M, et al. Botulinum toxin treatment for lower limb extensor spasticity in chronic hemiparetic patients. J Neurol Neurosurg Psychiatry 1994 Nov; 57(11): 1321–4PubMedCrossRef

42.

Hesse S, Krajnik J, Luecke D, et al. Ankle muscle activity before and after botulinum toxin therapy for lower limb extensor spasticity in chronic hemiparetic patients. Stroke 1996; 27: 455–60PubMedCrossRef

43.

Hesse S, Reiter F, Konrad M, et al. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo- controlled trial. Clin Rehabil 1998 Oct; 12(5): 381–8PubMedCrossRef

44.

Konstanzer A, Ceballos-Baumann AO, Dressnandt J, et al. Local injection treatment with botulinum toxin A in severe arm and leg spasticity. Nervenarzt 1993 Aug; 64(8): 517–23PubMed

45.

Lagalla G, Danni M, Reiter F, et al. Post-stroke spasticity management with repeated botulinum toxin injections in the upper limb. Am J Phys Med Rehabil 2000 Jul-Aug; 79(4): 377–84PubMedCrossRef

46.

Memin B, Pollak P, Hommel M, et al. Treatment of spasticity with botulinum toxin. Rev Neurol (Paris) 1992; 148(3): 212–4

47.

Panizza M, Castagna M, di Summa A, et al. Functional and clinical changes in upper limb spastic patients treated with botulinum toxin (BTX). Funct Neurol 2000 Jul-Sep; 15(3): 147–55PubMed

48.

Pierson SH, Katz DI, Tarsy D. Botulinum toxin A in the treatment of spasticity: functional implications and patient selection. Arch Phys Med Rehabil 1996 Jul; 77(7): 717–21PubMedCrossRef

49.

Reiter F, Danni M, Lagalla G, et al. Low-dose botulinum toxin with ankle taping for the treatment of spastic equinovarus foot after stroke. Arch Phys Med Rehabil 1998 May; 79(5): 532–5PubMedCrossRef

50.

Rodriquez AA, McGinn M, Chappell R. Botulinum toxin injection of spastic finger flexors in hemiplegic patients. Am J Phys Med Rehabil 2000 Jan-Feb; 79(1): 44–7PubMedCrossRef

51.

Rousseaux M, Kozlowski O, Froger J. Efficacy of botulinum toxin A in upper limb function of hemiplegic patients. J Neurol 2002 Jan; 249(1): 76–84PubMedCrossRef

52.

Sampaio C, Ferreira JJ, Pinto AA, et al. Botulinum toxin type A for the treatment of arm and hand spasticity in stroke patients. Clin Rehabil 1997 Feb; 11(1): 3–7PubMedCrossRef

53.

Viriyavejakul A, Vachalathiti R, Poungvarin N. Botulinum treatment for post-stroke spasticity: low dose regime. J Med Assoc Thai 1998 Jun; 81(6): 413–22PubMed

54.

Wang HC, Hsieh LF, Chi WC, et al. Effect of intramuscular botulinum toxin injection on upper limb spasticity in stroke patients. Am J Phys Med Rehabil 2002 Apr; 81(4): 272–8PubMedCrossRef

55.

Woldag H, Hummelsheim H. Is the reduction of spasticity by botulinum toxin a beneficial for the recovery of motor function of arm and hand in stroke patients? Eur Neurol 2003; 50(3): 165–71PubMedCrossRef

56.

Slawek J, Bogucki A, Reclawowicz D. Botulinum toxin type A for upper limb spasticity following stroke: an open-label study with individualised, flexible injection regimens. Neurol Sci 2005; 26: 32–9PubMedCrossRef

57.

Suputtitada A. Local botulinum toxin type A injections in the treatment of spastic toes. Am J Phys Med Rehabil 2002; 81: 770–5PubMedCrossRef

58.

Miscio G, Del Conte C, Pianca D, et al. Botulinum toxin in poststroke patients: stiffness modifications and clinical implications. J Neurol 2004; 251: 189–96PubMedCrossRef

59.

Finsterer J, Fuchs I, Mamoli B. Automatic EMG-guided botulinum toxin treatment of spasticity. Clin Neuropharmacol 1997 Jun; 20(3): 195–203PubMedCrossRef

60.

Oechsner M. Treatment of hip adductor spasticity with botulinum toxin type B. Nervenarzt 2002; 73: 1179–82PubMedCrossRef

61.

Sheean G. Neurophysiology of spasticity. In: Barnes MP, Johnson G, editors. Clinical management of spasticity and the upper motor neurone syndrome. Cambridge: Cambridge University Press, 2001: 12–78

62.

Graven-Nielsen T, Mense S. The peripheral apparatus of muscle pain: evidence from animal and human studies. Clin J Pain 2001; 17: 2–10PubMedCrossRef

63.

Francis J, You S, Satorius A, et al. Analgesic properties and mechanism of action of botulinum toxin type A (Botox) [abstract]. 5th International Conference on Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins; Denver (CO); 2005 Jun

64.

Verplancke D, Snape S, Salisbury CF, et al. A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clin Rehabil 2005; 19: 117–25PubMedCrossRef

65.

Reiter F, Danni M, Lagalla G, et al. Low-dose botulinum toxin with ankle taping for the treatment of spastic equinovarus foot after stroke. Arch Phys Med Rehabil 1998; 79: 532–5PubMedCrossRef

66.

Hesse S, Jahnke MT, Luecke D, et al. Short-term electrical stimulation enhances the effectiveness of Botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients. Neurosci Lett 1995; 201: 37–40PubMedCrossRef

67.

Page SJ, Elovic E, Levine P, et al. Modified constraint-induced therapy and botulinum toxin A: a promising combination. Am J Phys Med Rehabil 2003; 82: 76–80PubMedCrossRef

68.

Johnson CA, Wood DE, Swain ID, et al. A pilot study to investigate the combined use of botulinum neurotoxin type a and functional electrical stimulation, with physiotherapy, in the treatment of spastic dropped foot in subacute stroke. Artif Organs 2002; 26: 263–6PubMedCrossRef

69.

Shaari CM, George E, Wu BL, et al. Quantifying the spread of botulinum toxin through muscle fascia. Laryngoscope 1991; 101(9): 960–4PubMedCrossRef

70.

Cote TR, Mohan AK, Polder JA, et al. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol 2005; 53(3): 407–15PubMedCrossRef

71.

Bhatia KP, Munchau A, Thompson PD, et al. Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases. J Neurol Neurosurg Psychiatry 1999; 67(1): 90–3PubMedCrossRef

72.

Sheean GL, Murray NM, Marsden CD. Pain and remote weakness in limbs injected with botulinum toxin A for writer’s cramp. Lancet 1995; 346(8968): 154–6PubMedCrossRef

73.

Andrade LA, Borges V, Ferraz HB, et al. Botulinum toxin A: experience in the treatment of 115 patients. Arq Neuropsiquiatr 1997; 55: 553–7PubMedCrossRef

74.

Holzer SE, Ludlow CL The swallowing side effects of botulinum toxin type A injection in spasmodic dysphonia. Laryngoscope 1996; 106: 86–92PubMedCrossRef

75.

Tuite PJ, Lang AE. Severe and prolonged dysphagia complicating botulinum toxin A injections for dystonia in Machado-Joseph disease. Neurology 1996; 46: 846PubMed

76.

Comella CL, Tanner CM, DeFoor-Hill L, et al. Dysphagia after botulinum toxin injections for spasmodic torticollis: clinical and radiological findings. Neurology 1992; 42: 1307–10PubMedCrossRef

77.

Mezaki T, Kaji R, Kohara N, et al. Development of general weakness in a patient with amyotrophic lateral sclerosis after focal botulinum toxin injection. Neurology 1996; 46: 845–6PubMed

78.

Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999 Oct 22; 53(7): 1439-4653 (7)CrossRef

79.

Bakheit AM, Ward CD, McLellan DL. Generalised botulism-like syndrome after intramuscular injections of botulinum toxin type A: a report of two cases [letter]. J Neurol Neurosurg Psychiatry 1997 Feb; 62(2): 198PubMedCrossRef

80.

Bakheit AM. Botulinum toxin in the management of childhood muscle spasticity: comparison of clinical practice of 17 treatment centres. Eur J Neurol 2003; 10: 415–9PubMedCrossRef

81.

Borodic G. Myasthenic crisis after botulinum toxin [letter]. Lancet 1998; 352: 1832PubMedCrossRef

82.

Tarsy D, Bhattacharyya N, Borodic G. Myasthenia gravis after botulinum toxin A for Meige syndrome. Mov Disord 2000; 15: 736–8PubMedCrossRef

83.

Erbguth F, Claus D, Engelhardt A, et al. Systemic effect of local botulinum toxin injections unmasks subclinical Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1993; 56: 1235–6PubMedCrossRef

84.

Fasano A, Bentivoglio AR, Ialongo T, et al. Treatment with botulinum toxin in a patient with myasthenia gravis and cervical dystonia. Neurology 2005; 64: 2155–6PubMedCrossRef

85.

Lange DJ, Rubin M, Greene PE, et al. Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes. Muscle Nerve 1991; 14: 672–5PubMedCrossRef

86.

Costa J, Espirito-Santo C, Borges A. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev 2005; Jan 25(1): CD003633

87.

Costa J, Espirito-Santo C, Borges A. Botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev 2005; Jan 25(1): CD004315

88.

Nebe A, Schelosky L, Wissel J, et al. No effects on heart-rate variability and cardiovascular reflex tests after botulinum toxin treatment of cervical dystonia. Mov Disord 1996; 11: 337–9PubMedCrossRef

89.

Claus D, Druschky A, Erbguth F. Botulinum toxin: influence on respiratory heart rate variation. Mov Disord 1995; 10: 574–9PubMedCrossRef

90.

Girlanda P, Vita G, Nicolosi C, et al. Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatry 1992; 55: 844–5PubMedCrossRef

91.

Dressler D, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 2003; 49: 34–8PubMedCrossRef

92.

Molgo J, Lemeignan M, Thesleff S. Aminoglycosides and 3,4-diaminopyridine on neuromuscular block caused by botulinum type A toxin. Muscle Nerve 1987; 10: 464–70PubMedCrossRef

93.

Santos JI, Swensen P, Glasgow LA. Potentiation of Clostridium botulinum toxin aminoglycoside antibiotics: clinical and laboratory observations. Pediatrics 1981; 68: 50–4PubMed

94.

Newman WJ, Davis TL, Padaliya BB, et al. Botulinum toxin type A therapy during pregnancy. Mov Disord 2004; 19: 1384–5PubMedCrossRef

95.

Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 1995 Sep; 45(9): 1743–6PubMedCrossRef

96.

Kessler KR, Skutta M, Benecke R, et al. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. J Neurol 1999; 246: 265–74PubMedCrossRef

97.

Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003; 60: 1186–8PubMedCrossRef

98.

Comella CL, Jankovic J, Daggett S, et al. Interim results of an observational study of neutralizing antibody formation with the current preparation of botulinum toxin type a treatment for cervical dystonia [abstract]. Presented at the 56 Annual Meeting of the AAN, San Francisco (CA), 2004. Neurology 2004; 62Suppl. 5: A511

99.

Pistolesi D, Selli C, Rossi B, et al. Botulinum toxin type B for type A resistant bladder spasticity. J Urol 2004; 171: 802–3PubMedCrossRef

100.

Khalili AA, Harmel MH, Forster S, et al. Management of spasticity by selective peripheral nerve block with dilute phenol solutions in clinical rehabilitation. Arch Phys Med Rehabil 1964; 45: 513–9PubMed

101.

Halpern D, Meelhuysen FE. Phenol motor point block in the management of muscular hypertonia. Arch Phys Med Rehabil 1966 Oct; 47(10): 659–64PubMed

102.

Garland DE, Lilling M, Keenan MA. Percutaneous phenol blocks to motor points of spastic forearm muscles in head-injured adults. Arch Phys Med Rehabil 1984 May; 65(5): 243–5PubMed

103.

Nathan PW, Sears TA, Smith MC. Effects of phenol solutions on the nerve roots of the cat: an electrophysiological and histological study. J Neurol Sci 1965; 2(1): 7–29PubMedCrossRef

104.

Gracies J-M, Elovic E, McGuire JR, et al. Traditional pharmacologic treatments for spasticity. Part 1: local treatments. In: Mayer NH, Simpson DM, editors. Spasticity: etiology, evaluation, management and the role of botulinum toxin. New York: We Move Organization, 2002: 44–65

105.

Trigaux JP, Deceone B, Van Beers B. Focal necrosis of the ureter following CT-guided chemical sympathectomy Cardiovasc Intervent Radiol 1992; 15(3): 180–2PubMedCrossRef

106.

The Wemove Spasticity Study Group. Dosing, administration and a treatment algorithm for the use of botulinum toxin type A for adult-onset muscle overactivity in patients with an upper motorneuron lesion. In: Mayer NH, Simpson DM, editors. Spasticity: etiology, evaluation, management and the role of botulinum toxin. New York (NY): WeMove Organization, 2002: 154–65

107.

Kirazli Y, On AY, Kismali B, et al. Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double-blind trial. Am J Phys Med Rehabil 1998 Nov-Dec; 77 (6): 510–15CrossRef

108.

Sheean G. Botulinum toxin treatment of spasticity: why is it so hard to show a functional benefit? Curr Opin Neurol 2002; 14: 771–6CrossRef

Titel: Botulinum Toxin Treatment of Adult Spasticity
A Benefit-Risk Assessment
verfasst von: Dr Geoffrey Sheean
Publikationsdatum: 01.01.2006
Verlag: Springer International Publishing
Erschienen in: Drug Safety / Ausgabe 1/2006
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI: https://doi.org/10.2165/00002018-200629010-00003

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Botulinum Toxin Treatment of Adult Spasticity

A Benefit-Risk Assessment

Abstract

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2006

Short-Term Chloral Hydrate Administration and Cancer in Humans

Advances in Understanding Drug-Induced Neuropathies

The Erice Declaration

Valproic Acid in Epilepsy

Fulfilling an Unmet Need in Psoriasis

The Prevalence of Potential Drug-Drug Interactions in Patients with Heart Failure at Hospital Discharge